The selling is modest in absolute terms and negligible relative to market cap. These appear to be routine, pre-planned transactions following stock option exercises rather than a signal of fundamental concern. Traders should monitor for any changes in forward-looking statements or corporate guidance, but no immediate reaction is warranted.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 15 $574.96entry
- T+1 · 7mo ago +0.41%α +0.16% · $577.33
- T+5 · 7mo ago −0.15%α −1.79% · $574.11
- T+20 · 6mo ago +1.18%α −4.86% · $581.74
- T+60 · 4mo ago −3.91%α −11.31% · $552.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three United Therapeutics executives, including the CEO, CFO, and General Counsel, conducted open-market share sales totaling $459K over a 7-day period, following large non-cash derivative exercises. The sales represent less than 0.002% of the company's $25.4B market cap and appear to be part of pre-planned transactions following stock option exercises.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold $227K worth of shares (395 shares) across multiple days in the cluster window at prices between $569.78 and $575.29.
- CFO James Edgemond sold $298K worth of shares (520 shares) on April 16, following the exercise of 20,000 derivative securities at two different strike prices.
- EVP Paul Mahon sold $115K worth of shares (200 shares) on April 16, following the exercise of 16,600 derivative securities.
- Total open-market sales in the cluster: $459K, representing less than 0.002% of $25.4B market cap.
- Multiple non-cash derivative exercises occurred at $0 and at strike prices ($135.42, $146.03), indicating pre-scheduled option expirations or vesting events.
Financial Impact
$459,000 in open-market sales
Risk Factors
- Perception risk: Concentrated selling by top executives could be misinterpreted as lack of confidence, despite likely being mechanical.
- Execution risk: Future larger-scale sales could occur if more options are exercised and sold under Rule 10b5-1 plans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1776459415868 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers